Literature DB >> 3092727

Amyloid plaques in Creutzfeldt-Jakob disease stain with prion protein antibodies.

T Kitamoto, J Tateishi, T Tashima, I Takeshita, R A Barry, S J DeArmond, S B Prusiner.   

Abstract

Amyloid plaques are found in the brains of some patients with Creutzfeldt-Jakob disease (CJD) and all patients with a related transmissible disorder, Gerstmann-Sträussler syndrome (GSS). In scrapie, a prion disease of animals, amyloid plaques have been shown to be composed of prion proteins (PrP), which form filaments of relatively uniform diameter. We report here that antisera raised against hamster scrapie PrP specifically stain amyloid plaques in the brains of both humans and rodents with CJD as well as a human subject with GSS. Earlier studies showed that these antibodies react with both rodent and human CJD PrP. The immunostained congophilic amyloid plaques in rodent brains measured 10 to 30 micron in diameter and exhibited a Maltese cross appearance. Limited proteolysis enhanced immunostaining of amyloid plaques in human brain sections from patients with CJD or GSS. Presumably proteolysis increases the exposure of those epitopes shared by human and rodent PrP. The differences in immunoreactivity between rodent and human amyloid plaques are consistent with other findings showing that cellular genes, not infectious purified prions, encode PrP.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092727     DOI: 10.1002/ana.410200205

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  44 in total

1.  The primary structure of the prion protein influences the distribution of abnormal prion protein in the central nervous system.

Authors:  T Kitamoto; K Doh-ura; T Muramoto; M Miyazono; J Tateishi
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

2.  Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid.

Authors:  M Gasset; M A Baldwin; D H Lloyd; J M Gabriel; D M Holtzman; F Cohen; R Fletterick; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

3.  Concomitant Creutzfeldt-Jakob and Alzheimer diseases.

Authors:  J M Powers; Y Liu; L S Hair; R J Kascsack; L D Lewis; L A Levy
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

4.  Protease sensitivity and nuclease resistance of the scrapie agent propagated in vitro in neuroblastoma cells.

Authors:  K Neary; B Caughey; D Ernst; R E Race; B Chesebro
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

Review 5.  Gene therapy for misfolding protein diseases of the central nervous system.

Authors:  Waldy San Sebastian; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

Review 6.  Prion liposomes.

Authors:  R Gabizon; S B Prusiner
Journal:  Biochem J       Date:  1990-02-15       Impact factor: 3.857

7.  Contributions of neuronal prion protein on sleep recovery and stress response following sleep deprivation.

Authors:  Manuel Sánchez-Alavez; Bruno Conti; Gianluca Moroncini; José R Criado
Journal:  Brain Res       Date:  2007-05-22       Impact factor: 3.252

8.  Differences in scrapie-induced pathology of the retina and brain in transgenic mice that express hamster prion protein in neurons, astrocytes, or multiple cell types.

Authors:  Lisa Kercher; Cynthia Favara; Chi-Chao Chan; Richard Race; Bruce Chesebro
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Prion protein preamyloid and amyloid deposits in Gerstmann-Sträussler-Scheinker disease, Indiana kindred.

Authors:  G Giaccone; L Verga; O Bugiani; B Frangione; D Serban; S B Prusiner; M R Farlow; B Ghetti; F Tagliavini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

10.  Creutzfeldt-Jakob disease with codon 129 polymorphism (valine): a comparative study of patients with codon 102 point mutation or without mutations.

Authors:  M Miyazono; T Kitamoto; K Doh-ura; T Iwaki; J Tateishi
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.